Artiva Short Term Debt from 2010 to 2024

ARTV Stock   11.04  0.64  6.15%   
Artiva Biotherapeutics, Short Term Debt yearly trend continues to be fairly stable with very little volatility. Short Term Debt will likely drop to about 2.2 M in 2024. During the period from 2010 to 2024, Artiva Biotherapeutics, Short Term Debt regression line of quarterly data had mean square error of 794.6 B and geometric mean of  665,284. View All Fundamentals
 
Short Term Debt  
First Reported
2010-12-31
Previous Quarter
3.6 M
Current Value
2.2 M
Quarterly Volatility
1.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Artiva Biotherapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Artiva Biotherapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Interest Income of 2.7 M or Depreciation And Amortization of 2.4 M, as well as many indicators such as Price To Sales Ratio of 3.18, Dividend Yield of 0.0 or Days Sales Outstanding of 18.2. Artiva financial statements analysis is a perfect complement when working with Artiva Biotherapeutics, Valuation or Volatility modules.
  
Check out the analysis of Artiva Biotherapeutics, Correlation against competitors.

Latest Artiva Biotherapeutics,'s Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Artiva Biotherapeutics, Common over the last few years. It is Artiva Biotherapeutics,'s Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Artiva Biotherapeutics,'s overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Slightly volatile
   Short Term Debt   
       Timeline  

Artiva Short Term Debt Regression Statistics

Arithmetic Mean983,038
Geometric Mean665,284
Coefficient Of Variation114.99
Mean Deviation843,395
Median458,000
Standard Deviation1,130,431
Sample Variance1.3T
Range3.2M
R-Value0.65
Mean Square Error794.6B
R-Squared0.42
Significance0.01
Slope164,322
Total Sum of Squares17.9T

Artiva Short Term Debt History

20242.2 M
20233.6 M
20223.5 M
2021433 K

About Artiva Biotherapeutics, Financial Statements

Artiva Biotherapeutics, investors use historical fundamental indicators, such as Artiva Biotherapeutics,'s Short Term Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Artiva Biotherapeutics,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short Term Debt3.6 M2.2 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Artiva Stock Analysis

When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.